Lyudmila Bazhenova, MD, discusses the FDA’s expanded approval of taletrectinib for ROS1-positive non–small cell lung cancer.
|Articles|February 24, 2015
- NSCLC (Issue 6)
- Volume 6
- Issue 1
Challenges Oncologists Face in Treating Lung Cancer
Author(s)Roman Perez-Soler, MD
Roman Perez-Soler, MD, chairman and chief, department of medical oncology, Montefiore Medical Center, deputy director, Albert Einstein Cancer Center, discusses the challenges oncologists still face in lung cancer.
Advertisement
Roman Perez-Soler, MD, chairman and chief, department of medical oncology, Montefiore Medical Center, deputy director, Albert Einstein Cancer Center, discusses the challenges oncologists still face in lung cancer.
<<<
Articles in this issue
over 11 years ago
Nanovesicles as Targeted Therapy for Lung Cancerover 11 years ago
Prior Cancer Diagnosis Not Viable Exclusion From Lung Cancer Trialsover 11 years ago
Liquid Biopsy Use in NSCLC Clinical Practice on the Horizonover 11 years ago
Lung Cancer Screening: Implementing the New Protocolover 11 years ago
Maintenance Therapies for Patients with Non-Small Cell Lung Cancerover 11 years ago
Diagnostic Platforms for Lung Cancerover 11 years ago
Potential Modulator of NSCLC Metastasis IdentifiedAdvertisement
Related to this article
During a live event, Mary Jo Fidler, MD, and participants discussed how an intermediate-risk regimen, insurance resistance, and limited experience with trilaciclib shape neutropenia prevention in extensive-stage disease.
For Hispanic Heritage Month, Narjust Florez, MD, discusses lung cancer risk, biomarker testing, and trial access in Hispanic and Latinx patients.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Dostarlimab Receives FDA Approval for MSI-H/dMMR Locally Advanced Rectal Cancer
2
Dr Bazhenova on the Updated FDA Label for Taletrectinib in ROS1+ NSCLC
3
MC001 Receives FDA Fast Track Designation in Pancreatic Cancer
4
FDA Accepts NDA for UGN-103 in Recurrent LG-IR-NMIBC
5